DDIT3 and glaucoma: There are a number of potentially druggable stress pathways [107] and genetic manipulation or pharmacological inhibition of the ATF4–CHOP–GADD34 pathway has shown therapeutic benefit in the trabecular meshwork in murine and human glaucoma [108,109].This cellular model of pseudoexfoliation glaucoma cannot capture all features of this complex disease, but can provide some insight into disease pathogenesis and support the development of novel therapeutic interventions.